Histological assessment of therapeutic response in breast cancer

Breast Cancer

Volumn 23, Issue 4, 2016, Pages 540-545

  Horii, Rie ^a   Akiyama, Futoshi ^a  

^a CANCER INSTITUTE   (Japan)

Author keywords

Breast cancer; Histological assessment of therapeutic response; Neoadjuvant therapy; Pathology

Indexed keywords

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; CLINICAL PRACTICE; DISEASE FREE SURVIVAL; FEMALE; HISTIOCYTE; HISTOLOGY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; NEOADJUVANT THERAPY; PREMENOPAUSE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; TREATMENT RESPONSE; TUMOR VOLUME; BREAST NEOPLASMS; DIAGNOSTIC IMAGING; ECHOMAMMOGRAPHY; PATHOLOGY; PROCEDURES; STANDARDS; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENT;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; LYMPHATIC METASTASIS; NEOADJUVANT THERAPY; PATHOLOGY, CLINICAL; TREATMENT OUTCOME; ULTRASONOGRAPHY, MAMMARY;

EID: 84886406932     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/s12282-013-0499-6     Document Type: Article

References (12)

1. Wolmark N, Wang J, Mamounas E, Bryant J, Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monographs. 2001;30:96–102.
2. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer Trial 10902. J Clin Oncol. 2001;19:4224–37.
3. Rastogi P, Anderson SJ, Bear HD, Geyer CE, Kahlenbeg MS, Robidoux A, et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol. 2008;26:778–85.
4. Bonadonna G, Valagussa P, Brambilla C, Ferrari L, Moliterni A, Terenziani M, et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J Clin Oncol. 1998;16:93–100.
5. Bear HD, Anderson S, Smith RE, Geyer CE Jr, Mamounas EP, Fisher B, et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2006;24:2019–27.
6. Symmans WF, Peintinger F, Rajan R, Kuerer H, Valeri V, Assad L, et al. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007;25:4414–22.
7. Penault-Llorca F, Abrial C, Raoelfils I, Cayre A, Mouret-Reynier MA, Leheurter M, et al. Comparison of the prognostic significance of Chevallier and Sataloff’s pathologic classifications after neoadjuvant chemotherapy of operable breast cancer. Hum Pathol. 2008;39:1221–8.
8. Sahoo S, Lester SC. Pathology of breast carcinomas after neoadjuvant chemotherapy: an overview with recommendations on specimen processing and reporting. Arch Pathol Lab Med. 2009;133:633–42.
9. Kurosumi M, Akashi-Tanaka S, Akiyama F, Komoike Y, Mukai H, Nakamura S, et al. Histological criteria for assessment of therapeutic response in breast cancer (2007 version). Breast Cancer. 2007;15:5–7.
10. Smith IC, Heys SD, Hutcheon AW, Miller ID, Payne S, Gilbert FJ, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol. 2002;20:1456–66.
11. Von Minckwitz G, Untch M, Blohmer JU, et al. Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol. 2012;35(15):1796–804.
12. Mazouni C, Peintinger F, Wan-Kau S, et al. Residual ductal carcinoma in situ in patients with complete eradication of invasive breast cancer after neoadjuvant chemotherapy does not adversely affect patient outcome. J Clin Oncol. 2007;25(19):2650–5.